Annual report pursuant to Section 13 and 15(d)

Collaboration and License Agreements and Supply Agreements - Additional Information (Details)

v3.23.1
Collaboration and License Agreements and Supply Agreements - Additional Information (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2021
USD ($)
Mar. 31, 2023
USD ($)
Jun. 30, 2022
USD ($)
Program
PerformanceObligation
Apr. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Oct. 31, 2021
USD ($)
Aug. 31, 2020
USD ($)
Mar. 31, 2020
USD ($)
Feb. 29, 2020
USD ($)
Sep. 30, 2019
USD ($)
May 31, 2019
USD ($)
Jul. 31, 2018
USD ($)
Program
Aug. 31, 2017
Program
Jun. 30, 2021
USD ($)
Dec. 31, 2022
USD ($)
Installment
shares
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2020
shares
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Accounts receivable, reserve for credit losses         $ 0                   $ 0 $ 0  
Shares | shares                             167,780 167,780 167,780
Vaxcyte, Inc.                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Deferred revenue         0                   $ 17,500,000 $ 0  
Nonrefundable, non-creditable upfront payment receivable                             10,000,000.0    
Common stock fair value                             7,500,000    
Additional nonrefundable and noncreditable payment                             5,000,000.0    
Additional milestone payment                             60,000,000.0    
Regulatory milestones cash in payment                             $ 75,000,000.0    
Shares | shares                             167,780    
Number of installments | Installment                             2    
BioNova Option Agreement                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Deferred revenue                             $ 0    
Initial licensing option payment           $ 4,000,000.0                 4,000,000.0    
Maximum potential payments related to option exercise, development, regulatory, and commercial milestones           $ 199,000,000.0                      
Minimum term of royalties receivable based on annual net sales           10 years                      
Initial licensing option refundable payment           $ 4,000,000.0                      
Additional payment required to exercise license option           $ 12,000,000.0                      
2019 EMD Serono Supply Agreement                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Deferred revenue         0                   0 0  
BMS Agreement                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Number of programs advancing through preclinical development | Program                         4        
Contingent payments                     $ 275,000,000.0            
Deferred revenue         0                   0 0  
2018 BMS Master Services Agreement                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Deferred revenue         600,000                   3,100,000 600,000  
2018 Merck Agreement                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Deferred revenue         900,000                   0 900,000  
Milestone payment receivable upon initiation of IND enabling toxicology study                           $ 15,000,000.0      
2018 Merck Agreement | Merck Sharp & Dohme Corp                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Contingent payment received                             10,000,000.0    
Milestone payment received                             2,500,000 2,500,000  
Additional milestone payment received                             7,500,000    
Number of target programs | Program                       2          
Initial transaction price                       $ 60,000,000.0          
Upfront payment received                             60,000,000.0    
Revenue recognized                             $ 600,000 1,900,000  
Revenue recognition aggregate contingent payments eligible to receive                               500,000,000  
Milestone method revenue recognition description                             If one or more products from the target program is developed for non-oncology or a single indication, the Company will be eligible for reduced aggregate contingent payments. In addition, the Company is eligible to receive tiered royalties ranging from mid-single digit to low teen percentages on the worldwide sales of any commercial products that may result from the collaboration    
2018 Merck Agreement | Future Services on Collaboration Joint Steering Committee ("JSC")                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Contingent payment received                               15,000,000.0  
Remaining contingent payment received                               300,000  
Revenue recognized                             $ 300,000    
First Cytokine-Derivative Program | Merck Sharp & Dohme Corp                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Upfront payment received               $ 5,000,000.0                  
Extended research term               1 year                  
Transaction price $ 65,000,000.0             $ 65,000,000.0 $ 60,000,000.0         80,000,000.0      
Constrained variable consideration                 $ 5,000,000.0         15,000,000.0      
2020 Merck Master Services Agreement                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Deferred revenue         0                   0 0  
MDA Agreement | EMD Serono                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Contingent payment received                   $ 1,500,000       $ 2,000,000.0      
Milestone payment received             $ 1,000,000.0                    
Deferred revenue         0                   0 0  
Maximum amount eligible to receive for each product developed                             52,500,000    
Supply Agreement | Vaxcyte, Inc.                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Reimbursements expenses accruals         $ 2,300                   4,800,000 2,300  
Reimbursements expenses                             12,400,000 8,900,000  
Tasly License Agreement                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Minimum term of royalties receivable based on annual net sales         10 years                        
Nonrefundable upfront payment receivable         $ 40,000,000.0                   40,000,000.0 40,000,000.0  
Maximum potential payments related to development regulatory commercialization contingent payments and milestones       $ 350,000,000.0                     345,000,000    
Reduction of research and development expenses recognized                             0 0  
Upfront payment revenue not recognized         40,000,000.0                        
Initial licensing payment due       $ 25,000,000.0                          
Upfront payment revenue recognized                             25,000,000.0    
Upfront payment withholding tax amount                             2,500,000    
Tasly License Agreement | Scenario Forecast                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Initial licensing payment in escrow   $ 15,000,000.0                              
Astellas License and Collaboration Agreement                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Deferred revenue         $ 0                   86,100,000 $ 0  
Number of target programs | Program     3                            
Upfront payment received                             90,000,000.0    
Transaction price     $ 90,000,000.0                            
Nonrefundable, non-creditable upfront payment receivable                             90,000,000.0    
Number of performance obligations | PerformanceObligation     4                            
Recognition of up front payment     $ 89,100,000                            
Estimated service period     4 years                            
Maximum amount eligible to receive for development, regulatory and commercial milestones for each product candidate                             422,500,000    
Termination written notice period     30 days                            
Upfront payment revenue not recognized                             $ 32,600,000    
Astellas License and Collaboration Agreement | Future Services on Collaboration Joint Steering Committee ("JSC")                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Recognition of up front payment     $ 900,000